Incannex Healthcare IXHL 深 沪
已收盘 10-30 16:00:00 美东时间
2.52
-0.060
-2.33%
华盛通- 最 高2.6173
- 今 开2.58
- 成交量 10.29万股
- 最 低 2.50
- 昨 收 2.58
- 总市值 3161.25万
- 52周最高 14.91
- 市盈率 静 --
- 换手率 0.82%
- 52周最低 2.49
- 委 比 -48.15%
- 总股本 1254.46万
- 历史最高 10800.00
- 量 比 1.91
- 振 幅 4.55%
- 历史最低 2.40
- 每 手 1
- 风险率 3.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多财报速睇 | Incannex Healthcare 2026财年年度营收0.00亿美元，同比下降100.0%；归母净利润亏损0.19亿美元，同比亏损缩窄58.8%
华盛资讯9月25日讯，Incannex Healthcare公布2026财年年度业绩，公司年度营收0.00亿美元，同比下降100.0%，归母净利润亏损0.19亿美元，同比亏损缩窄58.8%。
09-25 21:01
Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position
Incannex Healthcare Inc. has initiated patient dosing in the DReAMzz Phase 2 study of IHL-42X for obstructive sleep apnea, received a U.S. patent for the drug with expiry in 2040, and holds approximately $70 million in cash with no debt. The company also reported positive results from the RePOSA Phase 2 study of IHL-42X and progress with its PSX-001 program for generalized anxiety disorder, including a Phase 2b study and regulatory engagement in ...
09-09 12:00
Incannex Begins Phase 2 DReAMzz Trial for IHL-42X
Incannex Healthcare Limited Sponsored ADR ( ($IXHL) ) has shared an update. On ...
08-25 19:55
Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026
<p>Incannex Healthcare has received a final A$5.1 million refund under the Australian Government’s Research and Development Tax Incentive Program, bringing the total to over A$11.2 million in non-dilutive capital. This strengthens the company’s balance sheet and financial flexibility, supporting its clinical pipeline and shareholder-focused initiatives.</p>
08-11 12:00
Incannex Begins Phase 2 DReAMzz Screening for IHL-42X
An announcement from Incannex Healthcare Limited Sponsored ADR ( ($IXHL) ) is n...
07-23 19:59
Incannex Healthcare Secures U.S. Patent For Compositions And Methods Of Treatment For Obstructive Sleep Apnea
The granted patent includes claims directed to the proprietary IHL-42X composition and its associated therapeutic methods for the treatment of Obstructive Sleep Apnea (OSA). The patent is expected to have a baseline expiry date of 9 July 2040 and the Company is exploring its eligibility for patent t...
06-25 20:05
Incannex Secures Key U.S. Patent for IHL-42X
The latest update is out from Incannex Healthcare Limited Sponsored ADR ( ($IXH...
06-25 19:57
Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
Incannex Healthcare Inc. announced the USPTO has granted a key patent for its IHL-42X composition and therapeutic methods to treat Obstructive Sleep Apnea (OSA). The patent, set to expire in 2040, strengthens the company's intellectual property and supports long-term market exclusivity. IHL-42X, a novel oral therapy, addresses significant unmet needs in OSA treatment, with poor patient adherence to current options. The patent, combined with FDA F...
06-25 12:00
Incannex Healthcare Secures Major Non-Dilutive R&D Funding
The latest update is out from Incannex Healthcare Limited Sponsored ADR ( ($IXH...
06-10 20:01
